Showing results (81-90 of 168) with videos related to

Sort By:
Pageof 17
Pharmacotherapy|May 8, 2013
Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research NetworkSherry K Milfred-LaForest, Sheryl L Chow, Robert J DiDomenico, et al.
JAMA Network Open|September 14, 2023
Temporal Association Among Influenza-Like Illness, Cardiovascular Events, and Vaccine Dose in Patients With High-Risk Cardiovascular Disease: Secondary Analysis of a Randomized Clinical TrialSheila M Hegde, Brian L Claggett, Jacob A Udell, et al.
European Heart Journal|June 29, 2025
Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statementBettina Heidecker, Peter Libby, Vassilios S Vassiliou, et al.
European Journal of Heart Failure|April 8, 2024
Effects of sacubitril/valsartan according to polypharmacy status in PARAGON-HFShingo Matsumoto, Mingming Yang, Li Shen, et al.
Journal of the American Heart Association|February 8, 2022
Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort StudyDaniel Modin, Brian Claggett, Mads Emil Jørgensen, et al.
Circulation. Heart Failure|August 8, 2020
Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical TrialsNosheen Reza, Ayman Samman Tahhan, Nadim Mahmud, et al.
JACC. Heart Failure|August 13, 2018
Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart FailureAnkeet S Bhatt, Li Liang, Adam D DeVore, et al.
European Journal of Heart Failure|June 8, 2021
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trialAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|November 30, 2019
Influence of Age on Efficacy and Safety of Spironolactone in Heart FailureOrly Vardeny, Brian Claggett, Muthiah Vaduganathan, et al.
JAMA Cardiology|April 7, 2024
Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical TrialAlexander Peikert, Brian L Claggett, Jacob A Udell, et al.
Pageof 17